PALO
ALTO, Calif., Feb. 4, 2025
/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a
biopharmaceutical company committed to researching, developing and
commercializing transformative therapeutics to treat a broad
spectrum of retinal diseases, announced today that senior
management will present the Company's pipeline program exploring
the treatment of glaucoma at the Glaucoma 360 New Horizons Forum
2025 on Friday, February 7, 2025, in
San Francisco, CA.
Glaucoma is the leading cause of irreversible blindness,
affecting approximately 76 million people worldwide. This optic
neuropathy progressively damages the optic nerve, leading to
partial or total vision loss. Emerging research identifies
neuroinflammation as a key driver of optic neuropathy in glaucoma,
but the primary focus of glaucoma therapy today is decreasing the
elevated intraocular pressure, the only modifiable risk factor of
the disease.
"At Kodiak Sciences, we are leveraging our Antibody Biopolymer
Conjugate Drug (ABCD) platform to develop a first-in-class,
disease-modifying therapy that decreases the neuroinflammation
driving optic neuropathy and simultaneously reduces the elevated
intraocular pressure", said Dolly
Chang, M.D., Ph.D., Chief Scientific Officer at Kodiak
Sciences. "This dual-acting approach has the potential to transform
glaucoma treatment by addressing the underlying mechanism of optic
nerve damage."
Kodiak's novel "duet" therapy, which will be presented at the
Glaucoma 360 New Horizons Forum, directly targets the NLRP3
inflammasome, a key driver of neuroinflammation and optic
neuropathy while also incorporating an IOP-lowering molecule to
reduce eye pressure. Designed for quarterly dosing, this innovative
dual-mechanism investigational therapy is designed to offer a
comprehensive and more durable solution to slow glaucoma
progression and improve long-term outcomes.
"With the ABCD platform, we aim to redefine glaucoma
treatment by delivering next-generation, disease-modifying,
multi-mechanism therapies that provide patients with more effective
and longer-lasting solutions," Dr. Chang added.
Presentation details are below:
Title: Addressing Optic Neuropathy Through
Neuroinflammation Modulation and IOP Lowering with the ABCD
Platform: A Polymedicine Approach to Glaucoma
Presenter: Dolly S. Chang, M.D., M.P.H., PH.D.,
Chief Scientific Officer, Kodiak Sciences Inc.
Date and time: February 7,
2025. This presentation is part of the broader session
titled "Beyond IOP: Targeting Neuroprotection and Vision
Restoration" scheduled from 10:45 - 11:55 a.m. PST.
Slides of the presentation will be available on the "Events and
Presentations" section of Kodiak's website at
http://ir.kodiak.com/ at the beginning of the
presentation.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical
company committed to researching, developing, and commercializing
transformative therapeutics to treat a broad spectrum of retinal
diseases. We are focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Our ABC Platform™
uses molecular engineering to merge the fields of protein-based and
chemistry-based therapies and has been at the core of Kodiak's
discovery engine. We are developing a portfolio of three clinical
programs, two of which are late-stage today and derived from our
ABC Platform and one which is platform-independent and which we
believe can progress rapidly into pivotal studies.
Kodiak's lead investigational medicine, tarcocimab, is a novel
anti-VEGF antibody biopolymer conjugate under development for the
treatment of high prevalence retinal vascular diseases. Tarcocimab
is currently being studied in two Phase 3 clinical trials, GLOW2 in
patients with diabetic retinopathy and DAYBREAK in patients with
wet AMD. Both studies are actively enrolling patients.
KSI-501 is our second investigational medicine, a first-in-class
anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate
designed to inhibit both IL-6 mediated inflammation and
VEGF-mediated angiogenesis and vascular permeability. KSI-501 is
being developed for the treatment of high prevalence retinal
vascular diseases to address the unmet needs of extended durability
and targeting disease biology beyond VEGF for differentiated
efficacy. The Phase 3 DAYBREAK study of KSI-501 in wet AMD is
actively enrolling patients.
KSI-101, our third product candidate, is a novel anti-IL-6,
VEGF-trap bispecific protein. Kodiak is developing KSI-101 for the
treatment of retinal inflammatory diseases, as currently there are
no available intravitreal biologic therapies addressing the
spectrum of inflammatory conditions of the retina. The Phase
1b APEX study of KSI-101 is actively
enrolling patients, as a precursor to activating the Phase
2b/3 PEAK and PINNACLE studies in
patients with macular edema secondary to inflammation
("MESI").
Kodiak is advancing its platform technology to embed small
molecules and other active pharmaceutical ingredients ("APIs") into
Kodiak's proprietary biopolymer backbone to enable high
drug-antibody-ratio ("DAR") medicines. The diverse APIs are
designed to be released over time to achieve targeted,
multi-specific and tailored modulation of biological pathways. The
unique combination of high DAR and tailored therapeutic benefit
offers potential for broad application to multifactorial diseases
and builds directly from our Antibody Biopolymer Conjugate
technology and its 15 years of design, development and
manufacturing experience. We call this platform extension our
Antibody Biopolymer Conjugate Drug ("ABCD") Platform because we are
extending our platform capabilities to include the conjugation of
small molecule drugs and other APIs whereas historically, we
primarily conjugated biologics such as antibodies.
For more information, please
visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding:
leveraging our ABCD platform to develop a potential first-in-class,
disease-modifying therapy that decreases the neuroinflammation
driving optic neuropathy and simultaneously reducing the elevated
intraocular pressure; the potential to transform glaucoma treatment
by addressing the underlying mechanisms of optic nerve damage; the
novel "duet" therapy's potential to offer a more durable and
comprehensive solution to slow glaucoma progression and improve
long-term outcomes; the aim to redefine glaucoma treatment by
delivering next-generation, disease-modifying and multi-mechanism
therapies that provide patients with longer-lasting and more
effective solutions; our ability to rapidly progress clinical
programs into pivotal studies; activating the Phase 2b/3 PEAK and PINNACLE studies in patients with
macular edema secondary to inflammation; the unique combination of
high DAR and tailored therapeutic benefit offering the potential
for broad application to multifactorial diseases; and our
platform's capabilities to include the conjugation of small
molecule drugs and other APIs. Forward-looking statements generally
include statements that are predictive in nature and depend upon or
refer to future events or conditions, and include words such as
"may," "will," "should," "would," "could," "expect," "plan,"
"believe," "intend," "pursue," and other similar expressions among
others. Any forward-looking statements are based on management's
current expectations of future events and are subject to risks and
uncertainties that could cause actual results to differ materially
and adversely from those in or implied by such forward-looking
statements. These risks and uncertainties include, but are not
limited to: the risk that cessation, modification or delay of any
of the ongoing clinical studies may occur; the risk that our
research and development efforts and our ability to advance our
product candidates into later stages of development may fail; the
risk that any one or more of our product candidates may not be
successfully developed, approved or commercialized; the risk that
adverse economic conditions may significantly impact our business
and operations, including our clinical trial sites, and those of
our manufacturers, contract research organizations or others with
whom we conduct business; the risk that sufficient capital may not
be available as expected, or at all, to complete the development of
any products; as well as the other risks identified in our filings
with the Securities and Exchange Commission (SEC). For a discussion
of other risks and uncertainties, and other important factors, any
of which could cause our actual results to differ from those
contained in the forward-looking statements, see the section
entitled "Risk Factors" in our most recent Form 10-K, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the SEC. These
forward-looking statements speak only as of the date hereof and
Kodiak undertakes no obligation to update forward-looking
statements, and readers are cautioned not to place undue reliance
on such forward-looking statements.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™, ABCD™ and the
Kodiak logo are registered trademarks or trademarks of Kodiak
Sciences Inc. in various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-glaucoma-360-new-horizons-forum-2025-302367078.html
SOURCE Kodiak Sciences Inc.
